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Abstract Detection of mutations in hereditary breast and
ovarian cancer-related BRCA1 and BRCA2 genes is an
effective method of cancer prevention and early detection.
Different ethnic and geographical regions have different
BRCA1 and BRCA2 mutation spectrum and prevalence.
Along with the emerging targeted therapy, demand and
uptake for rapid BRCA1/2 mutations testing will increase in
a near future. However, current patients selection and
genetic testing strategies in most countries impose signif-
icant lag in this practice. The knowledge of the genetic
structure of particular populations is important for the
developing of effective screening protocol and may provide
more efficient approach for the individualization of genetic
testing. Elucidating of founder effect in BRCA1/2 genes can
have an impact on the management of hereditary cancer
families on a national and international healthcare system
level, making genetic testing more affordable and cost-
effective. The purpose of this review is to summarize
current evidence about the BRCA1/2 founder mutations
diversity in European populations.
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Prediction and prevention
Introduction
The most significant and well characterized genetic risk
factors for breast and/or ovarian cancer to date are germline
mutations of the BRCA1 (MIM#113705; 17q chromosome;
[1]) and BRCA2 (MIM#600185; 13q chromosome [2])
genes. In the general population, about 5–10% of all breast
cancer and 10–15% of ovarian cancer cases can be
attributed to these major genetic risk factors, which can
explain around half of breast/ovarian cancer aggregation in
some families [3, 4]. The prevalence of BRCA1/2 mutation
carriers in the general population is around 0.2% (1/500)
what accounts for BRCA1 mutation rate carriers of around
1/800 [5], however it can vary significantly among different
countries or some ethnic groups due to founder effect [6].
The mutations in these high-penetrance genes confer a
high life-time risk of breast and ovarian cancer. Women
with an inherited BRCA1 mutation have a lifetime risk of
65–80% of developing breast cancer and 37–62% of
developing ovarian cancer, while BRCA2 mutation carriers
have a lifetime risk of 45–85% for breast cancer and 11–23%
for ovarian cancer [7].
The identification of BRCA1 and BRCA2 mutation carriers
and individualized risk assessment is an important procedure
growing in clinical importance, since management protocols
for mutation carriers become well established [8–10] and
proven life-saving, risk-reducing preventive medical inter-
ventions exist [11–13]. Once mutation is identified in a given
family, a very informative predictive (or presymptomatic)
oncogenetic test can be offered virtually to all adult family
members. Moreover, oncogenetic testing is becoming the
powerful therapeutical predictive tool, as new targeted
therapeutic opportunities, such as poly(ADP-ribose) (PARP)
inhibitors [14, 15], emerge and chemosensitivity to platinum
based therapy is constantly reported [16, 17].
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Currently, in most countries clinical BRCA1/2 testing is
offered after genetic counseling by clinical cancer geneticist
(oncogeneticist) when mutation finding probability exceeds
10%, or even 20% (as in the UK) [18]. Various selection
criteria, based on family history, age at onset and tumors
clinicopathological features, as well as computational risk
prediction models (Claus, BRCAPRO, BOADICEA, IBIS,
Myriad and Manchester scoring system [19, 20]) are used.
Unfortunately, these models often underestimate the proba-
bility of finding a mutation, are validated only in some
countries, are not particularly helpful for daily use and no
consensus exist regarding their common use [9, 21].
Moreover, familial history is also absent or unknown in at
least half of all mutation possitive families [22] and mutation
detection methods varies between most centers.
It is now evident, that in a near future the uptake and
demand for rapid BRCA1/2 mutations testing will increase
and more flexible genetic counseling strategies will be
needed. As new targeted therapies become available, more
individuals will request testing to get access to specific
treatments (i.e., PARP inhibitors), regardless of their a priori
low risk and clinicians will force laboratories towards rapid
testing results. This tendency is already seen in the centers
enroling patients for PARP inhibitors clinical trials (van
Osterweik, personal communication) as well as during
peridiagnostic (presurgical) testing for a newly diagnozed
breast cancer patients [23].
However, a full BRCA1 and BRCA2 gene screening still
remains labor and time consuming challenge due to large
genes size, diverse mutations or variants of unknown
significance (VUS) and complexity of large genomic rear-
angements (LGRs), requiring special technical approach.
This procedure still remains too complex and expensive to
cover a broader target (e.g. all breast or ovarian cancer
patients and their first degree relatives) and cannot be
routinely applied in less privileged countries.
Fortunately, recent advances in high-throughput mutation
detection and screening techniques, such as high resolution
melting (HRM) analysis [24] and conformation-sensitive
capillary electrophoresis (CSCE) [25] are especially promis-
ing rapid, sensitive, cost-efficient and ammenable for
automation screening approaches for the large genes,
whereas decreased cost in genotyping methods offers
affordable targeted testing option for predefined set of
mutations.
Massively parallel next-generation sequencing platforms
[26] provide another technological breakthrough, however
they are still at a prohibited cost and complex data overload
for routine use.
On the other hand, variation in the distribution of
BRCA1 and BRCA2 mutations is well recognized world-
wide [27] and several recent reviews already summarized
the evidence, that in certain countries and ethnic commu-
nities the BRCA1/2 mutation spectrum is limited to a few
founder mutations [3, 4, 6, 28]. Founder effects are most
prominent in geographically, culturally or religiously
isolated populations that undergo rapid expansion from a
limited number of ancestors, when, as a consequence of
low genetic diversity, some alleles become more frequent.
The purpose of this review is to summarize current
evidence about the BRCA1/2 founder mutations diversity in
European populations. For the current manuscript only the
unequivocally deleterious mutations were considered, ex-
cluding as yet the unclassified variants that could not be
clearly related with pathogenicity. For the consistency, the
unequivocal term “founder” is used for those mutations
where haplotype studies revealed shared polymorphic
markers consistent with common ancestor, or when
unrelated mutation carriers were repeatedly identified (at
least 3 times). Some mutations previously described as
founder mutations in one country, subsequently are found at
a higher proportion in other countries/regions as true
founders. These mutations in adjacent countries will likely
reflect the gradient transition from the “epicenter” over the
time due to historical co-existence of different populations
in the same region. Mutations that do not segregate with the
same alleles are referred as “recurrent”. They presumably
occurred several times at unstable ‘mutational hot spots’
parts of the gene. The mutation nomenclature will be
generally presented according to Human Genome Variation
Society (HGVS) recommendations (http://www.hgvs.org/
rec.html); only at the first mutation mention the older BIC
database (http://research.nhgri.nih.gov/bic/) nomenclature
will be used between the parentheses, where possible.
BRCA1 is numbered by GeneBank U14680 reference
sequence; BRCA2 is numbered by GeneBank U43746
reference sequence.
For the mutations distribution in other geographic
regions or more detailed prevalence, penetrance and
contribution to unselected for family history cancer cases,
readers are referred to other review sources [3, 4, 6, 27–30].
Founder BRCA1 and BRCA2 mutations
in European populations
Ashkenazi Jews
The BRCA1/2 founder effect in Ashkenazi Jews population
is very well described. About 10 millions Ashkenazi people
living worldwide are descendants of ancestors from Eastern
and Central Europe, such as Poland, Lithuania, Belarus,
Germany, Hungary, Ukraine and Russia. The most well
characterized three founder mutations are two in BRCA1
gene c.68_69delAG (BIC: 185delAG) and c.5266dupC
(BIC: 5382insC) and one in BRCA2 c.5946delT (BIC:
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6174delT) [31–33]. Screening for these three founder
mutations alone is now part of routine clinical practice for
Ashkenazi Jewish individuals.
These 3 mutations (BRCA1 c.68_69delAG, c.5266dupC
and BRCA2 c.5946delT) account for 98–99% of identified
mutations and are carried by about 2.6% (1/40) of the
Ashkenazi Jewish population (1%, 0.13% and 1.52%
respectively) [34–36]. There are differences between
particular mutations and breast/ovarian cancer risk [37].
The average risk of breast cancer by the age of 70 years is
similar for carriers of the BRCA1 c.68_69delAG and
c.5266dupC mutations (64% and 67% respectively), how-
ever is much lower for the c.5946delT mutation (43%). The
corresponding values for ovarian cancer lifetime risk is
respectively of 14%, 33% and 20% in carriers, respectively
[6, 37, 38].
It is worth noting that BRCA1 c.68_69delAG and
c.5266dupC are not found exclusively in Ashkenazi
patients. The c.68_69delAG mutation has been found in
patients of Spanish ancestry (i.e. Hispanic) as well as other
non-Ashkenazi ethnic groups, sometimes with frequencies
similar to those in Ashkenazi populations [3], suggesting a
common ancient ancestor or two independent mutational
events [39].
The c.5266dupC mutation in BRCA1 exon 20 is the
second most frequently reported mutation in the BIC
database, being very prevalent in Central and Eastern
Europe. This single mutation is found in a various
frequency in high risk breast and/or ovarian cancer families
from Poland (34%) [40], Russia (14%) [41], Hungary
(14%) [42], Slovenia (13%) [43], Ashkenazi Jews (10%)
[44], Greece (8%) [45], Germany (4%) [46], Italy (3%)
[47]. It is virtually absent in Spain and Portugal and is found at
low frequency in the Netherlands, Belgium and Scandinavian
countries [6]. In Russia, Belarus, Poland, Latvia, Czech
Republic, Greece and Lithuania this mutation accounts for
respectively 94% [48], 73% [49], 60% [40], 55% [50], 37–
52% [51, 52], 46% [45], 34% [53, 54] of all BRCA1
mutations.
Haplotype analysis points to the Baltic origin of this
mutation approximately 38 generations ago during the
medieval period [55], with a gradual decrease thereafter
from East to the West and nearly worldwide spread. A
common ancestor for c.5266dupC mutation families
reported from Europe, Brazil and North America is evident
[46, 56, 57].
Austria
In Austria the ratio of BRCA1 mutations to BRCA2
mutations is 2:1 (Rappaport, personal communication).
There were initial reports for several apparently founder
BRCA1 mutations in Austria [58, 59], although they
(c.181T>G (BIC: 300T>G/C61G), c.5266dupC,
c.1687C>T (BIC: 1806C>T)) represent common mutations
prevalent in other European countries. In Austria these
alterations represent 15%, 10% and 6% of the BRCA1
mutation families, respectively (Rappaport, personal com-
munication). Of note, c.1687C>T is also frequent in
Slovenia [43] and Sweden (BIC database). Haplotype
analysis revealed a common ancestor for the Austrian and
Swedish families, which may indicate Austrian origin of
this mutation [59], although its even more common in
Slovenia (26% of the BRCA1 mutation families) [43].
Another common mutation is BRCA1 c.3016_3019del4
(BIC: 3135del4) (8% of the BRCA1 mutation families),
which was also found in Italy [60]. One BRCA1 mutation
c.2676_2679del4 (BIC: 2795del4) was reported at least in
three unrelated families in Austria only, what may represent
founder effect [58, 59], however this mutation is uncom-
mon. The most prevalent BRCA2 mutations are c.8363G>A
(BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS21-
1G>A) and c.3860delA (BIC: 4088delA), representing 9%,
7% and 6% of the BRCA2 mutation families respectively
(Rappaport, personal communication).
Slovenia
In Slovenia five highly recurrent specific mutations were
identified: four in the BRCA1 gene (c.1687C>T, c.181T>G,
c.5266dupC, c.181T> (BIC: 300T>A)) and one in the
BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61,
62]. Respectively, they accounted for 26%, 18%, 13% and
11% of BRCA1 mutations and 56% of BRCA2 mutations.
The c.7806-2A>G in the BRCA2 gene appears to be an
unique founder mutation in the Slovenian population, found
in 26% (10/38) of all BRCA1/2 mutations harboring
families. These 5 mutations account for 67% of the
BRCA1/2 positive families [43].
Italy
In Italy, 4–27% of the identified mutations recurred among
apparently unrelated families, and significant regional
founder effect has been demonstrated for few mutations
[63–66].
Four distinct BRCA1 founder mutations (c.3228_
3229delAG (BIC: 3347delAG), c.3285delA (BIC:
3 4 0 4 d e lA ) , c . 1 3 8 0 d u pA (B IC : 1 4 9 9 i n sA ) ,
c.5062_5064del3 (BIC: 5181delGTT) accounted for a large
fraction (73%) of BRCA1-attributable hereditary breast/
ovarian cancer in families originating from Tuscany
(Central Italy) area [47, 66].
The BRCA1 c.1380dupA mutation was reported in at
least 14 families from Tuscany and originated here about 30
generations ago (∼750 years) [65].
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In Sardinia, contribution of BRCA1/2 mutations to breast
cancer predisposition has been reported for populations
from the Northern part of the island [67], where founder
BRCA2 c.8537_8538delAG (BIC: 8765delAG) mutation
comprises 28% for BRCA1/2 positive families [68, 69]. The
ratio of BRCA2 mutations to BRCA1 mutations is approx-
imately 2:1, although BRCA1 being more prevalent in
South-West area [68]. Conversely, previously regarded as
another founder mutation, BRCA2 3950_3952delTAGinsAT
was found instead running in families belonging to a single
extended pedigree [68].
The BRCA1 c.4964_4982del19 (BIC: 5083del19) is a
founder mutation from the southern region of Calabria and
accounted for 23% of all BRCA1 mutations [60, 63]. It was
also recurrently found at least four times in Sicilia [70, 71].
Another BRCA1 c.4724delC (BIC: 4843delC) mutation
could be a possible Sicilian founder mutation, although
present evidence is scarce [71–73].
Using a number of independent approaches, Malacrida et
al. [74] showed that previously reported BRCA1
c.5062_5064delGTT (BIC: 5181_5183delGTT/1688Val)
variant of unknown significance (VUS) actually is a
deleterious mutation with high frequency in North-East
Italy [74]. The founder c.5062_5064delGTT mutation
accounts for 15% (9/61) of families with small BRCA1
mutations.
France
In France geographical clustering in North-Eastern part is
evident for two recurrent BRCA1 mutations, suggesting a
founder effect. The c.3481_3491del11 (BIC: 3600del11) in
exon 11 accounts for 37% and the nonsense mutation
c.5128G>T (BIC: 5247G>T/Gly1710X) in exon 18 for
15% of all BRCA1/2 mutations in that region (overall 52%)
[4, 75].
The haplotype analysis of the families carrying the
mutation c.3481_3491del11, all originating from Alsace–
Lorraine, revealed the presence of a common allele, indicating
a founder effect [75]. Although this mutation is found in
many different geographical areas, it is more common in
France. The BRCA1 mutation c.5128G>T would appear to
be specific to the France, but the analysis of its haplotype is
less conclusive and needs further confirmation [6].
The BRCA1 c.5030_5033delCTAA (BIC: 5149delC-
TAA) [76] and c.3839_3843delinsAGGC (BIC:
3958delCTCAGinsAGGC) [77] mutations were reported
in at least three independent families from France.
Well-described founder mutations are identified in
French-Canadians population in Quebec, which originated
from France during 17–18th century settlement period. In
this region 4 BRCA1 gene mutations (c.4327C>T (BIC:
4446C>T/Arg1443X) , c .3756_3759de l4 (BIC:
3875de lGTCT) , c . 962G>A (BIC : 1081G>A) ,
c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3
BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5),
c.5857G>T (BIC: 6085G>T), c.8537_8538delAG (BIC:
8765delAG)) are now routinely included in early onset
breast/ovarian cancer screening assays and represent up to
84% of the total BRCA1/2 mutations in the French-
Canadian population in Quebec [78]. Among these, the
most common founder mutations are BRCA1 c.4327C>T
and BRCA2 c.8537_8538delAG and c.3170_3174del5,
which are found in 1.7% of women affected by breast
cancer diagnosed before age 41 and in 1.3% of women with
ovarian cancer [6].
Spain
In Spain, five mutations in BRCA1 and other five in BRCA2
genes account for approximately half of the mutations
detected in Spanish families. Specific mutations differ
significantly in their frequencies and geographic distribution.
A compilation of BRCA test results from different
laboratories shows that five mutations in the BRCA1 gene
(c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A
(BIC: 5236G>A), c.5123C>A (BIC: 5242C>A),
c.470_471delCT (BIC: 589_590delCT) account for 46.6% of
BRCA1 mutations and four mutations in BRCA2
(c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA
(BIC: c.6857delAA), c.9026_9030del5 (BIC: 9254-
9258del5), c.9310_9311delAA (BIC: 9538delAA)) account
for 56.6% of the BRCA2 mutations [79].
Diez et al., [80] have reviewed the frequency of BRCA1
and BRCA2 recurrent mutations reported in seven geo-
graphic areas of Spain.
The founder mutation BRCA1 c.211A>G, that leads to
aberrant splicing of the transcript, originates from North
Western Spain (Galicia) and accounts up to 50% of all
mutations in this region [81]. It was also found in French
and British families of Spanish origin [82].
The BRCA1 c.68_69delAG and BRCA2 c.9026_
9030del5 mutations accounted for the 30.4% (7/23) of the
BRCA1 mutations and for the 18.5% (5/27) of the BRCA2
positive families respectively and were specific only to the
Mediterranean areas. Indeed, haplotype studies indicated a
common origin of c.68_69delAG mutation in Spanish
(Sephardic Jewish) and Ashkenazi Jewish populations
[83]. Some data indicate an unique origin of reported
BRCA2 exon 23 mutation BRCA2 c.9026_9030del5 in
Catalan families (North-East Spain) [84]. Likewise, the
BRCA2 c.2808_2811del4 mutation was predominant only in
the Castilla-Leon region (Central Spain), but it also has been
described worldwide in many populations and is the second
recurrent pathological mutation in the BIC database ranking
with a presumable multiple different origins [85, 86].
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Splicing mutation c.5153-1G>A (BIC: 5272-1G>A) of
BRCA1 and frameshift mutation c.5146_5149del4 (BIC:
5374delTATG) of BRCA2 are also prevalent founder
mutations in the Central Spain region, accounting for
18.4% and 13.6% of BRCA1 and BRCA2 positive families,
respectively [80, 85, 87]. Such knowledge of the spectrum
of mutations and their geographical distribution can allow a
more effective detection strategy in countries with large
Spanish population.
Conversely, in the Basque population, only 1.2% (1/81)
of early onset breast cancer women unselected for family
history had pathological mutations; no founder mutation
was identified [88].
Portugal
An Alu sequence insertion in BRCA2 exon 3 (c.156_
157insAlu (BIC: 384insAlu)) is a founder mutation of
Portuguese origin and accounts for more than one-fourth of
deleterious BRCA1/2 mutations in breast/ovarian cancer
families in Northern/Central Portugal. This mutation creates
BRCA2 exon 3 skipping and is the most frequent large
BRCA2 rearrangement described to date [89, 90].
Belgium
Claes et al. [91] in a 49 BRCA1/2 positive families found six
major recurrent founder mutations (three BRCA1 c.212+3A>
(BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG),
c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A
(BIC: IVS6+1G>A), c .6275_6276delTT (BIC:
6503_6504delTT), c.8904delC (BIC: 9132delC) alterations),
which accounted for nearly 60% of all mutations identified.
BRCA1 c.212+3A>G was previously reported as Belgian
founder mutation [92, 93], later also found in a few German,
Dutch and French families [91]. BRCA1 c.2359dupG and
BRCA2 c.516+1G>A have not yet been reported in other
populations.
The Netherlands (Holland)
Several founder mutations in BRCA1/2 have been identified
in Holland [94], where significant regional and cultural
differences exist. The BRCA1 c.2685_2686delAA (BIC:
2804delAA) founder mutation probably originated approx-
imately 32 generations (∼200 years) ago, was also reported
few times in Belgium and accounted for 24% of all BRCA1/
2 mutations [92]. BRCA1 c.2193del5 (BIC: 2312del5), and
c.1292dupT (BIC: 1411insT) mutations were also com-
monly found [92, 94].
In the south-west of Holland two founder mutations: 3.8-kb
deletion of BRCA1 exon 13, also known as c.4186-
1643_4357+2020del3835 (BIC: del exon 13del3835/
IVS12-1643del3835), and BRCA2 c.5351dupA (BIC:
5579insA) were found in families from two different
geographical areas, and were prevalent respectively in
Catholic (West Braband clustering) and Protestant (South
Beveland clustering) families, reflecting religious endogamy
[95]. Together with another Dutch BRCA2 founder mutation
c.6275_6276delTT (BIC: 6503delTT), c.5351dupA accounts
for 62% of hereditary breast/ovarian families [94, 95].
Slightly outdated (as of year 2002) list of published and
unpublished BRCA1/2 mutations in Netherlands and Belgium
can be found at http://www.humgen.nl/lab-devilee/Lab/
b1nlmuts.htm.
Large genomic rearrangements (LGRs) in BRCA1 gene
are surprisingly common in Dutch population and more
than 30% of the BRCA1 related cases of hereditary breast
cancer are due to copy number changes of one or more
exon in this gene. The majority of these (25%) are due to
two frequently occurring founder mutations: already de-
scribed 3.8-kb deletion of exon 13 or 510-bp deletion of
exon 22 [96], which can be easily detected by multiplex-
ligation dependent probe amplification (MLPA) method.
Germany
The BRCA1 deletion of exon 17 accounts for 8% of all the
BRCA1 mutations and is the most frequent rearrangement
in Germany, found in 3% of high-risk families and in 6% of
families without point mutations [97]. Altogether, recurrent
aberrations such as deletion of exon 17, duplication of exon
13 and deletion of exon 22, accounts for more than 50% of
all BRCA1 large genomic rearrangements in Germany [98].
There was a large number of recurrent mutations with a
common haplotype identified in breast/ovarian cancer
patients [99]. Eighteen BRCA1 mutations, including the
most common c.5266dupC, c.181T>G, c.4065_4068del4
(BIC: 4184del4) and c.2338C>T (BIC: 2457C>T), were
found at least 3 times and comprised 66% of all BRCA1
mutations. The 2 most common BRCA1 c.5266dupC and
c.181T>G mutations, also prevalent in other populations,
accounted for 38% of BRCA1 mutations [4, 99]. Seven
distinct mutations accounted for 28% of BRCA2 mutations,
and most frequent c.1813dupA (BIC: 2041insA),
c.4478del4 (BIC: 4706del4) and c.9098dupA (BIC:
9326insA) were associated with common alleles, suggesting
a possible founder effect [99].
Czech Republic
Five mutations (BRCA1: c.181T>G, c.5266dupC, c.3700_
3704del5 (BIC: 3819del5), and BRCA2: c.7913_7917del5
(BIC: 8141del5) and c.8537_8538del2 (BIC: 8765delAG))
represented 52% of all mutations detected in one study
population [52]. There is evident strong Slavic founder
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effect, particularly for two BRCA1 mutations (c.181T>G
and c.5266dupC) also regarded as founder mutations in
Poland and some other Slavic countries [100]. The single
BRCA1 c.5266dupC mutation was detected in 51.4% of
BRCA1 mutation positive women in one study from Prague
area [51]. The BRCA1 c.3700_3704del5 mutation is also
frequent mutation in Germany [99]. Three BRCA1 Czech
founder mutations (c.181T>G, c.3700_3704del5, and
c.5266dupC) account for approximately 9%, 13% and 44%
of the BRCA1 mutations identified, respectively [51, 52].
BRCA1 mutations appears to be about 2 times more
frequent than BRCA2 mutations in the Czech population [52].
A Czech founder effect is evident for two BRCA2
mutations (c.7913_7917del5 and c.8537_8538del2), that
are more frequent in Moravian (Eastern) rather than in
Bohemian (Western) region [101]. These BRCA2 mutations
accounted for 15.6% and 16.7% of the BRCA2 mutations
identified in one study, respectively [52].
LGRs in BRCA1 gene are relatively common in Czech
population and account for 12.3% of all pathogenic BRCA1
mutations. The deletions of exons 1–17 and 5–14,
identified each in four families, represented Czech founder
mutations [102]. No LGRs in BRCA2 gene were described
so far.
Slovakia
The ratio of BRCA1 mutations to BRCA2 is approximately
9:2 and the most common BRCA1/2 mutations in Slovak
population are three common to the Ashkenazi mutations
(Zajac, personal communication). However, as yet there
are no convincing data about true BRCA1/2 mutational
spectrum in this population.
Hungary
In Hungarian patients from high-risk breast/ovarian cancer
families, common BRCA1 founder mutations c.5266dupC,
c.181T>G and c.68_69delAG accounted for 80% of all
BRCA1 mutations and c.9098dupA (BIC: 9326insA) with
c.5946delT accounted for 50% of all BRCA2 mutations [42,
103]. The BRCA1 c.181T>G is the most frequent of
founder mutations, representing 48% [103]. Breast cancer
patients were more likely to carry the c.5266dupC mutation
whereas ovarian patients were more likely to carry either
the c.68_69delAG or the c.181T>G mutation [103]. Among
unselected Hungarian male breast cancer patients, one third
carried BRCA2 mutations, including c.9098dupA [104].
Greece
In the Greek population four BRCA1 mutations (c.5526dupC,
c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC:
5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account
for 54% of all mutations detected in BRCA1/2 genes and for
73% of the BRCA1 mutations positive families, whereas the
rest are unique or low-frequency mutations, reflecting the
population’s genetic heterogeneity.
The most frequent BRCA1 mutation c.5526dupC
accounts for 31% of the BRCA1/2 mutations identified in
Greek familial breast/ovarian cancer patients [45, 105].
Previously described as unclassified BRCA1 missense
variant G1738R was proved to be pathogenic founder
mutation in Greece and accounts for about 12% of all
carriers with deleterious mutations in BRCA1/2 genes
[106].
Cyprus
In Cypriot breast cancer women proportion of BRCA2 to
BRCA1 gene mutations is approximately 2:1 [107]. The
BRCA2 c.8755delG (BIC: 8984delG) mutation was
reported in three unrelated families and could represent
Cypriot founder mutation [107, 108].
Denmark
BRCA1 and BRCA2 small scale mutations in Denmark are a
mixture of Scandinavian foundermutations and other European
mutations, including BRCA1 c.5266dupC. The most common
BRCA1 mutations were c.2475delC (BIC: 2594delC),
c.3319G>T (BIC: 3438G>T), c.5266dupC and c.3710delT
(BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of
BRCA1 positive families, respectively [109–111]. The
c.2475delC BRCA1 mutation was also reported in Sweden,
Norway and Western Europe (BIC database) and the
c.3319G>T BRCA1 mutation was also reported in Norway
(http://www.legeforeningen.no/id/153250.0).
The most common BRCA2 mutations were c.6373delA
(BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4),
c.6486_6489del4 (BIC: 6714del4) and c.3847_3848delGT
(BIC: 4075delGT), found in 11%, 10%, 9% and 5% of
BRCA2 positive families, respectively [111]. Two of the
recurrent BRCA2 mutations (c.1310_1313del4 and c.6486_
6489del4) have also been observed in many other pop-
ulations, whereas the c.6373delA BRCA2 mutation is less
frequent. There was a slight tendency towards a higher
frequency of BRCA2 families in West Denmark (56%)
compared to East Denmark (44%). Altogether 7 common
BRCA1/2 mutations (excluding c.5266dupC ) accounts for
around 35% of carriers [4].
LGRs in BRCA1 and BRCA2 are common in East
Denmark and account for 9.2% (15/163) of the disease
causing mutations. BRCA1 exons 3–16 deletion represents
Danish founder mutation, comprising 40% (6/15) of all
BRCA1/2 families with LGRs [112].
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Recently a pathogenic founder BRCA1 mutation
c.234T>G (BIC: 2466T>G/Cys39Gly) was desribed in
Greenland (Inuit population), an autonomous country
within the Kingdom of Denmark, with a high carrier
frequency (1.6%) in this population [113, 114]. Therefore
all women of Greenlandic origin are recommended to be
counseled and screened for this mutation [113].
Sweden
In Sweden, many different mutations in the BRCA1 and
BRCA2 genes have been detected. The most recurrent
BRCA1/2 mutation in Sweden is the single BRCA1
mutation c.3171_3175dup (BIC: 3171ins5), which origi-
nate from a limited geographic area along the west coast of
Sweden [115]. Mutation carriers have a conserved haplo-
type of 3,7 cM which is thought to have originated about 50
generations ago. In the western part of Sweden this
mutation accounts for 65–77% of identified mutations in
these two genes [116, 117]. Other common BRCA1
mutations in Sweden, c.2475delC and c.1082_1092del11
(BIC: 1201del11), have been detected primarily in families
from southern Sweden [118–120], Denmark and Norway
(BIC database). Another BRCA1 mutation, c.1687C>T,
occurs primarily in southern Sweden as well as other
European countries (BIC database). Yet another BRCA1
mutation c.3626delT (BIC: 3745delT) apparently originates
in northern Sweden and Finland [121].
The 6-kb duplication of BRCA1 exon 13, aslo known as
ins6kbEx13 (HGVS: c.4186-1787_4357+4122dup; BIC:
4305ins6000(dup_ex13) mutation, is quite common in
Sweden and is apparently specific to English-speaking
and related countries [122].
One BRCA2 mutation c.4258delG (BIC: 4486delG) is
found repeatedly in Swedish breast cancer families [120, 123].
In the Western Sweden, six mutations, including the
most common BRCA1 c.3171_3175dup, four other com-
mon Scandinavian BCRA1 mutations (c.1082_1092del11,
c.2475delC, c.1687C>T, c.1016dupA (BIC: 1135insA)) and
one BRCA2 mutation (c.4258delG) accounted for approx-
imately 75% of all BRCA1/2 mutations [124]. The founder
mutation, BRCA1 c.3171_3175dup, may explains more
than 80% of excess number of ovarian cancer after breast
cancer in this region [115, 125].
Norway
Four Norwegian founder mutations in BRCA1 gene
(c.1556delA (BIC: 1675delA), c.3228delAG (BIC:
3347delAG), c.697delGT (BIC: 816delGT) and
c.1016dupA make up 68% of the BRCA1 mutation carriers
[126, 127], and these have their own specific geographic
distribution. The first three originate from the south-western
region of the country, while the fourth is from the south-
east [127].
These four founder mutations together with other six
most frequent BRCA1/2 mutations (BRCA1 c.3178G>T
(BIC: 3297G>T), c.4745delA (BIC: 4864delA), c.2351del7
(BIC: 2470del7), c.3084del11 (BIC: 3203del11) and
BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC:
4075delGT)), account for about 60% BRCA1/2 carriers in
Norway [128]. BRCA1 c.1A>C (BIC: 120A>C) and
c.5075-2A>C (BIC: IVS17-2A>C) mutations are also
locally frequent. The large deletion of BRCA1 exons 1–13
is frequently found as well as exon 13 duplication
(ins6kb13Ex) (http://www.inherited-cancer.com).
The BRCA1 c.1016dupA mutation has also been reported
in other countries (Italy, Germany, French-Canada), however
allelotyping results indicated an independent origin of this
mutation. That would justify the inclusion of this mutation
into targeted BRCA1 mutation screening panels in any
population, irrespective of ethnic origin [129].
Finland
In the Finnish population, at least 13 recurrent BRCA1/2
mutations with a founder effect have been identified (6 in
BRCA1 and 7 in BRCA2 gene), and these represent majority
(around 84%) of all BRCA1/2 mutations detected [130–138].
The most common BRCA1 mutations are c.4097-2A>G (BIC:
4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT
(BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2
(BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T). The
c.5266dupC is also found relatively frequently.
The most recurrent mutation in BRCA2 is the Icelandic
founder mutation c.771_775del5 (BIC: 999del5), three
other (c.7480C>T (BIC: 7708C>T), c.8327T>G (BIC:
8555T>G), c.9118-2A>G (BIC: 9346-2A>G) and following
(c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC:
4081insA) and c.5569G>T (BIC: 5797G>T)). Some muta-
tions are unique to the Finns, such as c.4096+3A>G (BIC:
IVS11+3A>G) in BRCA1 and c.9117+1G>A (BIC: 9345+
1G>A), c.7480C>T, c.8327T>G in BRCA2 genes.
The mutation spectrum in Eastern part slightly differs
from those observed in the Northern and Southern parts of
the country [139].
Large genomic alterations are uncommon in BRCA1 or
BRCA2 gene in the Finnish population [140–142], and only
one LGR was found so far in BRCA1 [143].
Iceland
In Iceland, the most common single founder mutation is
c.771_775del5 in the BRCA2 gene [144, 145], which
accounts for virtually all breast/ovarian cancer families
and simplifies genetic testing. It occurs in 0.4% (1/250) of
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the population, 8.5% of consecutive unselected breast
cancer cases, 7.9% of ovarian cancer cases and 40% of
male breast cancer cases [6, 146].
The BRCA1 c.5074G>A (BIC: 5193G>A) is another
founder mutation recently identified in Icelandic popula-
tion, however it is extremely rare and contributes only to
1% of breast/ovarian cancer cases [147].
The profound founder effect in Iceland can be traced to
comparatively small number of women, mostly originating
from Scandinavia and the British Isles [148].
United Kingdom
There is some evidence about specific recurrent mutations
confined to particular geographic regions in the UK.
In one study from Scotland and Northern Ireland 10
specific recurring mutations (five in each gene) accounted
for almost half of the total mutations detected, and almost
one-quarter were accounted by just two founder mutations
(BRCA1 c.2681_2682delAA (BIC: 2800delAA) and
BRCA2 c.6275_6276delTT (BIC: 6503delTT) [149]. The
BRCA1 c.2681_2682delAA, probably originated from the
West-Central Scotland or Ireland [150]. BRCA2
c.6275_6276delTT has been found elsewhere in the UK
as well as in Dutch, Swedish, Danish and Belgian families
(BIC database).
In the North-west of England two reccurent mutations
(BRCA1 c.4065_4068del4 and BRCA2 c.1929delG (BIC:
2157delG) accounted for 16% of identified BRCA1 mutations
in breast/ovarian cancer families and for 20% of BRCA2
positive male breast cancer families, respectively, what is
around 1 in 8 of every mutation identified in each gene [151].
A duplication of a 6-kb fragment including BRCA1 exon
13 (ins6kbEx13), which creates a frameshift in the coding
sequence, is considered to be a common founder mutation
originating from Northern Britain [152] and comprise for
9% of BRCA1 mutations in UK [4, 152]. It is distributed
mainly in English-speaking countries or in countries with
historical links with Britain.
Ireland
A single BRCA1 c.427G>T (BIC: 546G>T/E143X) muta-
tion accounts for about 22% of all hereditary breast cancer
patients from relatively homogenous Irish population and
presumably is due to the founder effect [153].
Poland
There is strong founder effect in Polish population for
BRCA1 gene mutations. In Poland 3 most common
mutations (c.5266dupC, c.181T>G and c.4035delA (BIC:
4154delA) accounted for 91% (111/122) BRCA1 mutations
detected and for 86% of all detected mutations in BRCA1/2
genes [40, 100]. The BRCA1 c.5266dupC, c.181T>G and
c.4035delA accounted for about 56%, 25% and 10% of all
BRCA1 mutations, respectively. Mutations in BRCA2 gene
comprises for about 5.4% of all BRCA1/2 mutations
identified [40]. One of three BRCA1 founder mutations
was identified in 13.5% (49/364) consecutive ovarian
cancer cases and in 32.8% (58/177) women with familial
ovarian cancer in Western Poland, therefore its reasonable
to recommend genetic testing to all invasive ovarian cancer
cases regardless the age [154].
Data from other groups indicate, that mutational BRCA1/2
spectrum in Poland is more dispersed and different in various
subregions [155, 156]. In North-Eastern Poland two common
mutations (c.5266dupC and c.181T>G) accounted for more
than half (up to 70%) of all BRCA-mutated families and no
c.4035delA was identified [156], what is in accordance with
other studies [157]. By adding two other recurring BRCA1
mutations (c.68_69delAG and c.3700_3704del5), the vast
majority (87%) of mutation-positive families will be encom-
passed. At least 2 novel BRCA1 LGRs were found in Poland
and they are not so uncommon [157].
In fact, observed BRCA1 founder mutations are by no
means unique for Poland but rather of global or European
distribution [156] and its necessary to extend analysis,
including LGR, among patients negative for BRCA1/2
founder mutations.
Latvia
In Latvia two BRCA1 mutations (c.5266dupC and
c.4035delA) made up more than 80% of all mutations
BRCA1 identified [50, 158]. The 4154delA mutation is the
second most abundant BRCA1 gene mutation after the
c.5266dupC in Latvia [50] and is especially common for
patients of Baltic (Latvian and Lithuanian) origin. It was
also reported several times from Russia, Poland, has been
predominantly detected in individuals of Eastern European
and also is the most characteristic BRCA1 mutation in
Lithuania [53, 54]. A common shared haplotype, with
probable Lithuanian origin, was reported in these mutation
carriers [159]. The BRCA1 c.181T>G is the third recurrent
mutation in Latvia, but is not very commonly found. There
are no data present about BRCA2 mutation profile in
Latvia.
Lithuania
In Lithuania BRCA1 gene mutations are influenced by
significant founder effect, which is similar to that reported
from Latvian (Baltic) population [50]. BRCA1 c.4035delA
and c.5266dupC attributes to 86% (53% and 33% respec-
tively) of detected BRCA1 mutations [53, 54, 160]. Two
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Table 1 Most common and founder BRCA1/2 mutations in European populations
Population BRCA1 mutation BRCA2 mutation
HGVS BIC HGVS BIC
Ashkenazi Jews c.68_69delAG 185delAG c.5946delT 6174delT
c.5266dupC 5382insC
Austrian c.181T>G 300T>G c.8363G>A 8591G>A
c.5266dupC 5382insC c.8754+1G>A IVS21-1G>A
c.1687C>T 1806C>T c.3860delA 4088delA
c.3016_3019del4 3135del4
c.2676_2679del4 2795del4








Italian (Calabria) c.4964_4982del19 5083del19
Italian (North-East) c.5062_5064delGTT 5181_5183delGTT
French c.3481_3491del11 3600del11
c.5128G>T 5247G>T
Spanish c.68_69delAG 185delAG c.2808_2811del4 (Castilla-Leon) 3036_3039del4
c.211A>G (Galicia) 330A>G c.6629_6630delAA c.6857delAA
c.5117G>A 5236G>A c.9026_9030del5 9254-9258del5
c.5123C>A 5242C>A c.9310_9311delAA 9538delAA
c.470_471delCT 589_590delCT c.5146_5149del4 374delTATG
c.5153-1G>A 5272-1G>A
Portuguese c.156_157insAlu 384insAlu
Belgian c.212+3A>G IVS5+3A>G c.516+1G>A IVS6+1G>A
c.2359dupG 2478insG c.6275_6276delTT 6503_6504delTT
c.3661G>T 3780G>T c.8904delC 9132delC
Dutch c.2685_2686delAA 2804delAA c.5351dupA 5579insA
c.2193del5 2312del5 c.6275_6276delTT 6503delTT
c.1292dupT 1411insT
exon 13 deletion (3,8-kb)
exon 22 deletion (510-bp)
German exon 17 deletion c.1813dupA 2041insA
c.5266dupC 5382insC c.4478del4 4706del4
c.181T>G 300T>G c.9098dupA 9326insA
c.4065_4068del4 4184del4
c.2338C>T 2457C>T
Czech c.181T>G 300T>G c.7913_7917del5 8141del5




Hungarian c.5266dupC 5382insC c.9098dupA 9326insA
c.181T>G 300T>G c.5946delT 6174delT
c.68_69delAG 185delAG
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Table 1 (continued)
Population BRCA1 mutation BRCA2 mutation






Danish c.2475delC 2594delC c.6373delA 6601delA
c.3319G>T 3438G>T c.1310_1013del4 1538del4
c.5266dupC 5382insC c.6486_6489del4 6714del4
c.3710delT 3829delT c.3847_3848delGT 4075delGT
exons 3-16 deletion






exon 13 duplication (ins6kbEx13)
Norwegian c.1556delA 1675delA c.2808del4 3036del4












Finnish c.4097-2A>G 4216-2A>G c.771_775del5 999del5
c.3485delA 3604delA c.7480C>T 7708C>T
c.3626delT 3745delT c.8327T>G 8555T>G
c.4327C>T 4446C>T c.9118-2A>G 9346-2A>G




British c.2681_2682delAA (Scotland) 2800delAA c.6275_6276delTT (Scotland) 6503delTT
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other mutations, BRCA1 c.181T>G and recently proved to
be pathogenious c.5258G>C (BIC: 5377G>C/R1753T)
were also found in more than one family; together with
two founder mutations they comprise around 90% of
BRCA1 gene mutations and around 85% of all BRCA1/2
mutations identified (Janavičius, unpublished data). Rapid
screening of three BRCA1 amplicons by HRM analysis now
is the innitial procedure for breast/ovarian cancer patients in
our hospital.
The most frequently observed is BRCA1 c.4035delA
mutation, which is more frequent in families of Baltic
(Lithuanian) origin rather than Slavic [53, 54, 161], and
was detected in 16.3% (7/43) of unrelated ovarian cancer
patients unselected for family history in one study [159].
Among BRCA1 positive patients in a single population, this
particular mutation has the highest proportion identified to
date (53%), where in neighbouring countries (Latvia,
Poland, Belarus and Russia) it accounts for around 40%
[Tihomirova, personal communication], 10% [40], 9% [49]
and 9% [41] respectively of all BRCA1 mutations. This
distribution is in agreement with geographic area of ancient
Baltic people. Currently haplotype studies have been
innitiated to confirm further the occurence and timing of
this mutation in Lithuania.
Estonia
Newly published data from Estonia about BRCA1/2
mutations structure showed significant involvement of
BRCA1 c.5266dupC and to a lesser extent BRCA1
c.4035delA [162], what could be also expected projecting
data from adjacent countries.
Belarus
Only one small study in West Belarus for targeted BRCA1
mutations identified similar spectrum of 3 common muta-
tions as in Poland, and c.5266dupC accounted here for 73%
of all BRCA1 mutations [49].
Russia
In Russia the most common BRCA1 gene mutation in
c.5266dupC, comprising around 90% of all BRCA1
mutations [41, 163–167]. Other less common mutations
found in Western Russia are c.4035delA, c.181T>G, and
c.68_69delAG. In Siberian region of Russia there is seen
preponderance of individual BRCA2 gene mutations [164].
Other countries
In some countries, such as Romania, Bulgaria, Ukraine,Malta,
Albania and most previous Yugoslavian countries (Serbia,
Bosnia and Herzegovina, Macedonia and Montenegro) it
seems no surveys on BRCA1 and BRCA2 mutations have
been yet conducted and no data are available. From Croatia
no conclusive data about founder BRCA1/2 mutations pattern
is available, since only some individual mutations and
harmless variants were reported in one study [168].
Conclusions
The distribution of mutations in a European populations is
characterized by the genetic homogeneity or heterogeneity
of particular populations (Table 1). A stepwise mutation
screening protocol, based on initial screening for the
common mutations, is possible in populations with a high
proportion of founder mutations, allowing for a more rapid,
less expensive and hence, more affordable first-line genetic
testing strategy. However, subsequent full BRCA1/2 testing
is mandatory in most populations, probably with the
exception for Ashkenazi and Icelandic individuals, where
effect of few founder mutations is nearly absolute. The
contribution of LGRs should be also acknowledged for
most populations and specific techniques must be consid-
ered to achieve full coverage of BRCA1/2 genes. It is
possible that common founder mutations remain to be
identified in some populations.
Table 1 (continued)
Population BRCA1 mutation BRCA2 mutation






Apparently true founder mutations are written in italic. Nomenclature is given according HGVS (Human Genetic Variation Society)
recommendations and BIC (Breast Cancer Information Core) database. BRCA1 numbered by GeneBank U14680 reference sequence; BRCA2
numbered by GeneBank U43746 reference sequence
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Knowledge about mutation distibution diversity is
important not only for the consideration of country specific
cost-efficient strategy for mutation screening, but also for
the breast-ovarian cancer control and prevention through
more liberal, yet rational, genetic testing and counseling in
a globalized landscape of postmodern Europe. Common
genetic variation (e.g. single nucleotide polymorphisms
(SNPs)) might also influence disease risks in BRCA1/2
carriers and this subject is being addressed on a larger scale
by the Consortium of Investigators of Modifiers of BRCA1
and BRCA2 (CIMBA) which aims to identify genetic
modifiers of breast and ovarian cancer risk in BRCA1 and
BRCA2 carriers [169]. This information might be useful for
more precise risk estimation in the near future.
Personalized treatment era, based on comprehensive and
rapid BRCA1/2 genetic test result is nearly here. However,
taken the profoud and broad impact of possitive genetic
testing result for patients and their relatives, the importance
of pre- and post-test oncogenetic counseling still remain
essential.
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